Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | NPY2R | P49146 | 2/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RORC | P51449 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5765556 | 0.79 | CYP2D6 (0.55) | CYP2D6KCNH2HRH3LMNAEPHX2 | |
| SCHEMBL28405167 | 0.79 | LMNA (0.36) | CYP2D6KCNH2HRH3LMNANPY2R | |
| SCHEMBL4465716 | 0.79 | CYP2D6 (0.34) | CYP2D6KCNH2HRH3LMNANPY2R | |
| Hydrochloric Acid SCHEMBL29034671 | 0.78 | CYP2D6 (0.53) | CYP2D6KCNH2HRH3LMNAEPHX2 | |
| SCHEMBL28965487 | 0.77 | NR1H2 (0.33) | CYP2D6KCNH2HRH3HSD11B1 | |
| SCHEMBL28642318 | 0.76 | DPP4 (0.33) | CYP2D6KCNH2HRH3LMNAALDH1A1 | |
| SCHEMBL1049997 | 0.76 | CYP2D6 (0.40) | CYP2D6KCNH2HRH3LMNANPY2R | |
| SCHEMBL3552647 | 0.76 | CYP2D6 (0.40) | CYP2D6KCNH2HRH3LMNAEPHX2 | |
| SCHEMBL12536121 | 0.75 | NCF1 (0.38) | — | |
| SCHEMBL4475027 | 0.75 | HSD17B10 (0.39) | CYP2D6LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110678177-B | Pyrazole MAGL inhibitors | H.隆德贝克有限公司 | 2023-06-13 | — | — | CN | disclosed |
| US-7538111-B2 | Benzenesulphonamide derivatives, method for production and use thereof for treatment of pain | LABORATOIRES FOURNIER S.A. (FR) | 2009-05-26 | — | — | US | disclosed |
| US-20060178360-A1 | Benzenesulphonamide derivatives, method for production and use thereof for treatment of pain | LABORATOIRES FOURNIER S.A. (FR) | 2006-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060178360-A1 | Benzenesulphonamide derivatives, method for production and use thereof for treatment of pain | LTB4R2, BDKRB2, TBXA2R | CYP2D6 59/4885KCNH2 464/4885HRH3 863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.